10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
REGENERON PHARMACEUTICALS, INC. | ||
Ticker: REGN Fiscal Year: 2013 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2013 10-K (Filed: Feb 13, 2014) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2013 | Dec 31, 2012 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $ 535,608 | 230,276 |
| Marketable securities | 158,376 | 77,819 |
| Accounts receivable - trade, net | 787,071 | 593,207 |
| Accounts receivable from Sanofi | 104,707 | 99,913 |
| Inventories | 70,354 | 28,638 |
| Deferred tax assets | 44,677 | 148,134 |
| Prepaid expenses and other current assets | 96,141 | 28,025 |
| Total current assets | 1,796,934 | 1,206,012 |
| Restricted cash and marketable securities | 0 | 8,186 |
| Marketable securities | 389,891 | 271,230 |
| Property, plant, and equipment, at cost, net of accumulated depreciation and amortization | 526,983 | 379,940 |
| Deferred tax assets | 231,878 | 192,022 |
| Other assets | 5,327 | 23,100 |
| Total assets | 2,951,013 | 2,080,490 |
| LIABILITIES and STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | 250,896 | 111,345 |
| Deferred revenue from Sanofi, current portion | 12,815 | 17,022 |
| Deferred revenue - other, current portion | 34,185 | 33,809 |
| Facility lease obligations, current portion | 939 | 1,374 |
| Total current liabilities | 298,835 | 163,550 |
| Deferred revenue from Sanofi | 76,522 | 76,520 |
| Deferred revenue - other | 107,677 | 131,822 |
| Facility lease obligations | 184,258 | 159,436 |
| Convertible senior notes | 320,315 | 296,518 |
| Other long term liabilities | 11,330 | 7,259 |
| Total liabilities | 998,937 | 835,105 |
| Commitments and contingencies (Note 13) | ||
| Stockholders' equity: | ||
| Preferred Stock | 0 | 0 |
| Additional paid-in capital | 2,045,857 | 1,763,508 |
| Accumulated deficit | (92,692) | (517,054) |
| Accumulated other comprehensive loss | (1,188) | (1,166) |
| Total stockholders' equity | 1,952,076 | 1,245,385 |
| Total liabilities and stockholders' equity | 2,951,013 | 2,080,490 |
| Class of Stock | ||
| Class A Stock | ||
| Common stock | 2 | 2 |
| Common Stock | ||
| Common stock | 97 | 95 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2013 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |